Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NT 201 for lower limb spasticity in children and adolescents with cerebral palsy
2021-001634-18Phase 3Active
- Sponsor
- Merz
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of botulinum toxin type A in cerebral palsy (CP) (3 arms), sponsored by Merz. Primary endpoint: Change in derived modified Ashworth Scale score of plantar flexors. Started Jan 2022; status: active.
02
Drugs
botulinum toxin type A
03
Conditions
cerebral palsy (CP)
Beyond the preview
Go deeper on 2021-001634-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-001634-18.